Vivani Medical completes dosing of all 20 participants in Phase 1 trial of NPM-139 semaglutide implant

Vivani Medical, Inc.

First 10 participants dosed July 29, 2026; remaining 10 dosed one week later; all insertions successful.
Top-line data from the 20-participant SLIM-1 trial expected in November 2026.
Trial includes low-dose NPM-139 and Wegovy comparator to assess safety, tolerability, PK, and weight change.
Preclinical studies demonstrated sustainable 20% weight reduction in animal models.
July 2026 agreement with Novo Nordisk to evaluate NPM-139 and NanoPortal implant technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.